1 citations
,
March 2025 in “Skin Appendage Disorders” Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
April 2026 in “Human Genome Variation” Long-read RNA sequencing can identify complex gene changes in IFAP syndrome.
April 2025 in “Indian Journal of Paediatric Dermatology” Trichorrhexis invaginata can occur with tinea capitis, though it's rare.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
July 2023 in “Indian Journal of Endocrinology and Metabolism” An 11-year-old girl's hair regrew after treating her thyroid condition with carbimazole.
1 citations
,
March 2024 in “PubMed” Tick bites can cause localized hair loss.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
Botulinum toxin type A reduces itch and inflammation from histamine and may help treat certain skin conditions and hair loss.
August 2024 in “Skin Research and Technology” TAF can be identified by excessive skin thickening and clogged hair follicles, helping distinguish it from similar skin conditions.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
December 2013 in “Appetite” A defective gene causes hair loss and taste insensitivity in BTBR mice.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
January 2025 in “Dermatologic Surgery” Botulinum toxin injections can safely increase hair count in androgenetic alopecia.
July 2024 in “Journal of Investigative Dermatology” Recombinant human TSG-6 speeds up wound healing in diabetic mice.
32 citations
,
March 2013 in “EMBO journal” The plant hormone auxin activates the TOR pathway, affecting gene expression related to growth and cell size.
April 2023 in “Journal of Investigative Dermatology” COVID-toes show a unique immune response over time, different from vaccine-related chilblains.
October 2024 in “Intisari Sains Medis” Combining secretome with other treatments quickly improves eyebrow hair growth in alopecia areata.
August 2023 in “Journal of Cosmetic Dermatology” Higher concentration of botulinum toxin A is safe and effective for treating hair loss in men and women.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
The 7.5% talok and 2% pare leaf extract hair tonic effectively promotes hair growth, similar to minoxidil.
28 citations
,
May 2012 in “Experimental Dermatology”
2 citations
,
January 2024 in “Wiadomości Lekarskie” AI can greatly improve medical education by personalizing learning and enhancing skills, but challenges like cost, training, and ethics need addressing.